Teligent Regains Compliance with NASDAQ Listing Requirements
Teligent, Inc. (NASDAQ: TLGT) announced on June 22, 2020, that it has regained compliance with NASDAQ Listing Rule 5450(a)(1), which mandates a minimum bid price of $1.00 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Teligent, Inc. (NASDAQ: TLGT) announced on June 22, 2020, that it has regained compliance with NASDAQ Listing Rule 5450(a)(1), which mandates a minimum bid price of $1.00 per share. This determination comes after the company maintained a closing bid price of at least $1.00 for 10 consecutive business days, following a previous non-compliance notice received on June 5, 2019. Teligent aims to lead the specialty generic prescription drug market.
Positive
- Regained compliance with NASDAQ Listing Rule 5450(a)(1) on June 18, 2020.
- Maintained a closing bid price of $1.00 or greater for 10 consecutive business days.
Negative
- Previously received a non-compliance notice from NASDAQ on June 5, 2019.
Details
News Market Reaction – TLGT
The recorded move for TLGT in the trading session of this news was +6.27%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BUENA, N.J., June 22, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, announced today that it received notice from The NASDAQ Stock Market LLC (“NASDAQ”) on June 18, 2020 indicating that the Company has regained compliance with NASDAQ Listing Rule 5450(a)(1), which requires the Company’s common stock to maintain a minimum bid price of
NASDAQ had previously notified the Company of its non-compliance with NASDAQ Listing Rule 5450(a)(1) on June 5, 2019, following 30 consecutive business days for which the closing bid price of the Company’s common stock did not meet the
About Teligent, Inc.
Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market. Learn more on our website www.teligent.com.
| Contact: | Damian Finio Teligent, Inc. (856) 336-9117 www.teligent.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.